Dear Members of the Duchenne community,

Today we announced positive interim results from the ongoing FORWARD-53 clinical trial evaluating the investigational molecule WVE-N531 in boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. WVE-N531 is given every other week at 10mg/kg and the primary objective of this study is to evaluate dystrophin protein expression. For this interim analysis, we evaluated dystrophin and other measures after 24 weeks of treatment.

We are grateful to the Duchenne community for providing feedback on our development program since we began working in DMD many years ago and our goal today is to update you on our progress.

What we've learned from the interim (6-month) FORWARD-53 data:

- WVE-N531 was safe and well tolerated.
- WVE-N531 gets into muscle tissue in high concentrations of ~41,000 ng/g.
- WVE-N531 produces mean exon skipping of 57%.
- WVE-N531 treatment led to substantial dystrophin expression in a planned analysis of ambulatory participants:
    - Mean absolute muscle content-adjusted dystrophin of 9.0% and unadjusted dystrophin of 5.5%. Dystrophin was produced consistently across the boys, with the majority above 5% when adjusted for muscle content.
    - Dystrophin was present in two isoforms that are consistent with those observed in boys with Becker muscular dystrophy who display milder disease.
- Muscle biopsies also showed signs of improvement in muscle health, and that WVE-N531 was present in the right area of muscle cells to lead to dystrophin production. WVE-N531 was also present in muscle satellite cells, which have the potential to aid muscle regeneration.
- Data supports monthly dosing going forward, rather than dosing every other week.

What happens next?

We are encouraged by these data and plan to complete the study through 12 months (48-weeks) to allow us to learn more, including the effect of WVE-N531 on functional outcomes.

We also plan to meet with regulators to discuss next steps for WVE-N531 and look forward to sharing a program update in the first quarter of 2025.

Our gratitude

All of us at Wave would like to extend our deepest thanks to the clinical trial participants, their families, investigators, and clinical site staff who have dedicated their time and effort to FORWARD-53. Your continued commitment is critical to advancing WVE-N531 and the discovery and development of new treatments for DMD, which we hope will help improve the lives of people across the DMD community.

We look forward to continuing to advance our WVE-N531 program and sharing future updates as they are available.

Sincerely,

Chelley Casey, VP Patient Advocacy
ccasey@wavelifesci.com